Suven Pharmaceuticals
Suven Pharmaceuticals Performance
Day Range
- Low
- High
52 Week Range
- Low
- High
- Open Price
- Previous Close
- Volume
Start SIP in Suven Pharmaceuticals
Start SIPSuven Pharmaceuticals Investment Rating
-
Master Rating:
-
Suven Pharmaceuticals has an operating revenue of Rs. 1,334.82 Cr. on a trailing 12-month basis. An annual revenue growth of 38% is outstanding, Pre-tax margin of 47% is great, ROE of 29% is exceptional. The company has a reasonable debt to equity of 2%, which signals a healthy balance sheet. The stock from a technical standpoint is trading below to its 50DMA and close to its 200DMA. It needs to take out the 50DMA levels and stay above it to make any further meaningful move. From an O'Neil Methodology perspective, the stock has an EPS Rank of 77 which is a FAIR score but needs to improve its earnings, a RS Rating of 56 which is POOR indicating the underperformance as compared to other stocks, Buyer Demand at B- which is evident from recent demand for the stock, Group Rank of 84 indicates it belongs to a poor industry group of Medical-Generic Drugs and a Master Score of C is fair but needs to improve. Overall, the stock has mediocre earnings and technical strength, there are superior stocks in the current market environment.
EPS Strength
Price Strength
Buyer Demand
Group Rank
| Indicator | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 |
|---|---|---|---|---|
| Oper Rev Qtr Cr | 348 | 278 | 339 | 364 |
| Operating Expenses Qtr Cr | 201 | 172 | 184 | 206 |
| Operating Profit Qtr Cr | 147 | 107 | 155 | 158 |
| Depreciation Qtr Cr | 11 | 11 | 11 | 10 |
| Interest Qtr Cr | 1 | 0 | 1 | 2 |
| Tax Qtr Cr | 38 | 27 | 40 | 55 |
| Net Profit Qtr Cr | 109 | 79 | 114 | 224 |
Suven Pharmaceuticals Technicals
EMA & SMA
- Bullish Moving Average
- ___
- 2
- Bearish Moving Average
- ___
- 14
- 20 Day
- 476.32
- 50 Day
- 479.09
- 100 Day
- 476.3
- 200 Day
- 477.68
- 20 Day
- 476.35
- 50 Day
- 484.77
- 100 Day
- 473.85
- 200 Day
- 464.8
Suven Pharmaceuticals Resistance and Support
| Resistance | |
|---|---|
| First Resistance | 475.54 |
| Second Resistance | 480.77 |
| Third Resistance | 484.89 |
| RSI | 35.1 |
| MFI | 19.58 |
| MACD Single Line | -3.16 |
| MACD | -3.64 |
| Support | |
|---|---|
| First Resistance | 466.19 |
| Second Resistance | 462.07 |
| Third Resistance | 456.84 |
Suven Pharmaceuticals Delivery and Volume
| Period | NSE + BSE Volume Avg | NSE + BSE Delivery Volume Avg | NSE + BSE Delivery Volume % |
|---|---|---|---|
| Day | 234,555 | 19,116,233 | 81.5 |
| Week | 175,169 | 14,898,157 | 85.05 |
| 1 Month | 190,293 | 15,638,259 | 82.18 |
| 6 Month | 344,602 | 21,678,884 | 62.91 |
Suven Pharmaceuticals Result Highlights
Suven Pharmaceuticals Synopsis
NSE-Medical-Generic Drugs
Suven Pharmaceutical is involved in the business activities of Manufacture of pharmaceuticals, medicinal chemical and botanical products. Company’s Total Operating Revenue is Rs. 1320.22 Cr. and Equity Capital is Rs. 25.46 Cr. for the Year ended 31/03/2022. Suven Pharmaceuticals Ltd. is a Public Limited Listed company incorporated on 06/11/2018 and has its registered office in the State of Telangana, India. Company’s Corporate Identification Number(CIN) is L24299TG2018PLC128171 and registration number is 128171.| Market Cap | 11,942 |
| Sales | 1,330 |
| Shares in Float | 10.18 |
| No of funds | 154 |
| Yield | 0.64 |
| Book Value | 7.84 |
| U/D Vol ratio | 0.9 |
| LTDebt / Equity | 2 |
| Alpha | -0.02 |
| Beta | 0.4 |
Suven Pharmaceuticals
| Owner Name | Dec-22 | Sep-22 | Jun-22 | Mar-22 |
|---|---|---|---|---|
| Promoters | 60% | 60% | 60% | |
| Mutual Funds | 8.97% | 8.28% | 6.32% | |
| Insurance Companies | 2.23% | 2.24% | ||
| Foreign Portfolio Investors | 8.11% | 7.58% | 8.49% | |
| Financial Institutions/ Banks | ||||
| Individual Investors | 14.01% | 14.69% | 16.86% | |
| Others | 6.68% | 7.21% | 8.33% |
Suven Pharmaceuticals Management
| Name | Designation |
|---|---|
| Mr. Venkateswarlu Jasti | Managing Director |
| Ms. Deepanwita Chattopadhyay | Independent Director |
| Dr. Jerry Jeyasingh | Non Exe.Non Ind.Director |
| Mr. J V Ramudu | Chairman, Non Ind & Non Exe Director |
| Mr. D G Prasad | Independent Director |
| Dr. V Sambasiva Rao | Independent Director |
Suven Pharmaceuticals Forecast
Price Estimates
Suven Pharmaceuticals FAQs
What is Share Price of Suven Pharmaceuticals ?
Suven Pharmaceuticals share price is ₹468 As on 22 March, 2023 | 02:30
What is the Market Cap of Suven Pharmaceuticals ?
The Market Cap of Suven Pharmaceuticals is ₹11928.9 Cr As on 22 March, 2023 | 02:30
What is the P/E ratio of Suven Pharmaceuticals ?
The P/E ratio of Suven Pharmaceuticals is 31.5 As on 22 March, 2023 | 02:30
What is the PB ratio of Suven Pharmaceuticals ?
The PB ratio of Suven Pharmaceuticals is 7.8 As on 22 March, 2023 | 02:30